Are Prescription Drug Prices High?
- 24 May 1991
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 252 (5009), 1080-1084
- https://doi.org/10.1126/science.252.5009.1080
Abstract
The U.S. pharmaceutical industry has been criticized because its products are perceived to be too expensive, yet prescription medicines remain the least expensive form of therapy. At this time, we are experiencing a dramatic increase in the risks and costs of pharmaceutical research and development (R&D). An example may be seen in the R&D history of lovastatin. The U.S. pharmaceutical industry continues to lead the world in the discovery and development of important new medicines because it assumes greater financial risk and invests more of its sales dollar in R&D than virtually any other industry. Where such a risk is posed, there must continue to be the potential for profits. Pharmaceutical companies must set responsible prices, must keep price increases down, and must help improve access to important medicines.Keywords
This publication has 24 references indexed in Scilit:
- Cost of innovation in the pharmaceutical industryJournal of Health Economics, 1991
- Preclinical evaluation of lovastatinThe American Journal of Cardiology, 1988
- Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.JCI Insight, 1984
- Economic Analysis of a New Drug: Potential Savings in Hospital Operating Costs from the Use of a Once-Daily Regimen of a Parenteral CephalosporinClinical Infectious Diseases, 1984
- Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.JCI Insight, 1982
- Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme a reductaseAtherosclerosis, 1982
- Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activityFEBS Letters, 1976
- γ,γ‐Dimethyl‐allyl‐pyrophosphat und Geranyl‐pyrophosphat, biologische Vorstufen des Squalens Zur Biosynthese der Terpene, VI1)Angewandte Chemie, 1959
- Isolation of a New Acetate-replacing FactorJournal of the American Chemical Society, 1956
- THE UTILIZATION OF β-HYDROXY-β-METHYL-δ-VALEROLACTONE IN CHOLESTEROL BIOSYNTHESISJournal of the American Chemical Society, 1956